Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with platinum-based chemotherapy then maintenance pembrolizumab within its marketing authorisation for the treatment of advanced or recurrent endometrial cancer.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6381

Provisional Schedule

Committee meeting: 1 04 February 2025
Expected publication 16 April 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Endometriosis Foundation
  Endometriosis UK
  Eve Appeal
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Peaches Womb Cancer Trust
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Wellbeing of Women
  Womb Cancer Support UK
  Women’s Health Concern
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Clinical Cytology
  British Society for Colposcopy and Cervical Pathology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians and Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Assessment group Public Health Wales
  UK Health Security Agency
Comparator companies Accord (carboplatin, paclitaxel, cisplatin, doxorubicin)
  Alliance Healthcare (cyclophosphamide, paclitaxel)
  Bausch & Lomb (megestrol acetate)
  Baxter Healthcare (cyclophosphamide)
  Bristol Myers Squibb Pharmaceuticals (paclitaxel)
  Consilient Health (carboplatin)
  Fresenius Kabi (carboplatin, paclitaxel)
  Hospira UK (carboplatin, paclitaxel)
  Johnson & Johnson Innovative Medicine (doxorubicin)
  Medac GmbH (doxorubicin)
  Novartis (cisplatin, cyclophosphamide)
  Pfizer (carboplatin, paclitaxel, cisplatin,
  doxorubicin, medroxyprogesterone
  acetate)
  Sandoz (cyclophosphamide)
  Seacross Pharmaceuticals (paclitaxel, doxorubicin)
  Teva UK (carboplatin, paclitaxel)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
08 July 2024 Invitation to participate
20 May 2024 - 18 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6381
20 May 2024 In progress. Scoping commencing
24 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
24 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual